Moneycontrol.comNatco Pharma inks pact with MabxienceIBNLive.comThree of these products -Trastuzumab, Bevacizumab, Rituximab belong to the oncology segment, while Etanercept is for auto-immune disease, Natco said in a statement. Natco's obligations…

ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small …MarketWatch (press release)Rituximab, azathioprine, methotrexate, or mycophenolate mofetil therapy are also used, but these drugs are associated with an increased risk of infec…

RTT NewsFall in Avastin sales and strong franc hurt Roche financialsPharma TimesThe firm's top-selling drug in the quarter was MabThera/Rituxan (rituximab), for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arth…

NICE recommends RoActemra for early use in arthritisInPharmThis updates its previous guidance (TA198) from last August, which said RoActemra should only be used for patients with RA if there has been an inadequate response to one or more TNF inhibitors…

Four growth drivers beyond patent for pharma companies like Sun Pharma, SanofiEconomic TimesAhead of the Pack: When launched in India in 2007, Dr Reddy's Reditux, a brand of cancer drug rituximab, was the first biosimilar of Roche's $6 billion …

Mucocutaneous Paraneoplastic Syndromes Associated With Hematologic MalignanciesCancer NetworkTreatment guidelines are not available, but case series point to the use of rituximab (Rituxan) as well as corticosteroids and various other immunomodulating a…

Arthritis care announced support for new treatmentBarchester HealthcareIn 2010, Nice recommended tocilizumab as a means of treating people with arthritis if there has been an inadequate response to one or more TNF inhibitors and where rituximab has als…

University of Rochester NewsroomScientists Look to Immune System to Handle Follicular LymphomaUniversity of Rochester NewsroomIt builds on previous work by this team at the James P. Wilmot Cancer Center at the UR, in which they proved that the drug Rit…

NICE provisional OK for RoActemra in RAPharma TimesIn August 2010, NICE issued guidance TA198, which recommends RoActema as an option for people with RA if there has been an inadequate response to one or more tumour necrosis factor (TNF) inhibitors and…

Rituximab success paves way for plant produced mAbsIn-PharmaTechnologist.comiBio is expanding use of its green plant technology to biosimilar mAbs after producing rituximab using the system. Producing rituximab, marketed as Mabthera, using non-transgen…